XT
NRSN icon

XTX Topco’s NeuroSense Therapeutics NRSN Stock Holding History

XTX Topco’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.26K Buy
+11,473
New +$8.94K ﹤0.01% 4044
2025
Q2 		– Sell
-33,706
Closed -$31K – 2915
2025
Q1 		$31K Sell
33,706
-8,191
-20% -$9.06K ﹤0.01% 2070
2024
Q4 		$50.3K Sell
41,897
-4,099
-9% -$4.71K ﹤0.01% 1896
2024
Q3 		$58.4K Buy
45,996
+13,346
+41% +$12.7K ﹤0.01% 1675
2024
Q2 		$36.6K Buy
+32,650
New +$41.6K ﹤0.01% 1541

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $86.2M AUM 41.28% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

XTX Topco's NRSN Position: Q2 2026 in Review

XTX Topco opened a new position in NeuroSense Therapeutics (NRSN) in Q2 2026: 11,473 shares worth $8.26K. The stake represents ﹤0.01% of the portfolio and ranks #4044 among its holdings. This is a return to the name: XTX Topco previously reported a position in NRSN as recently as Q1 2025.

XTX Topco first reported a position in NRSN in Q2 2024 and has held it in 5 quarters since. The position peaked at $58.4K in Q3 2024. 12 funds tracked by Wall St. Rank hold NRSN as of Q2 2026.

  • XTX Topco held 11,473 shares of NeuroSense Therapeutics worth $8.26K as of Q2 2026.
  • NeuroSense Therapeutics was a new XTX Topco position in Q2 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #4044 holding.
  • XTX Topco first reported a position in NeuroSense Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • XTX Topco's NeuroSense Therapeutics position peaked at $58.4K in Q3 2024.
  • 12 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.